294 related articles for article (PubMed ID: 33040433)
21. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
Zhu FC; Chen W; Hu YM; Hong Y; Li J; Zhang X; Zhang YJ; Pan QJ; Zhao FH; Yu JX; Zhang YS; Yang X; Zhang CF; Tang H; Zhang H; Lebacq M; David MP; Datta SK; Struyf F; Bi D; Descamps D;
Int J Cancer; 2014 Dec; 135(11):2612-22. PubMed ID: 24740596
[TBL] [Abstract][Full Text] [Related]
23. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
[TBL] [Abstract][Full Text] [Related]
24. The difference in the effectiveness of human papillomavirus vaccine based on smoking status.
Hikari T; Honda A; Hashiguchi M; Okuma R; Kurihara M; Fukuda A; Okuma E; Nakao Y; Yokoyama M
J Obstet Gynaecol Res; 2022 Jul; 48(7):1859-1866. PubMed ID: 35599387
[TBL] [Abstract][Full Text] [Related]
25. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.
Baldur-Felskov B; Dehlendorff C; Munk C; Kjaer SK
J Natl Cancer Inst; 2014 Mar; 106(3):djt460. PubMed ID: 24552678
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study.
Tozawa-Ono A; Kamada M; Teramoto K; Hareyama H; Kodama S; Kasai T; Iwanari O; Koizumi T; Ozawa N; Suzuki M; Kinoshita K
Hum Vaccin Immunother; 2021 Apr; 17(4):950-954. PubMed ID: 33121340
[TBL] [Abstract][Full Text] [Related]
27. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
28. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
[TBL] [Abstract][Full Text] [Related]
29. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
30. Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.
Benard VB; Castle PE; Jenison SA; Hunt WC; Kim JJ; Cuzick J; Lee JH; Du R; Robertson M; Norville S; Wheeler CM;
JAMA Oncol; 2017 Jun; 3(6):833-837. PubMed ID: 27685805
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.
Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F
Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783
[TBL] [Abstract][Full Text] [Related]
32. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
[TBL] [Abstract][Full Text] [Related]
33. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).
Young EJ; Tabrizi SN; Brotherton JM; Wark JD; Pyman J; Saville M; Wrede CD; Jayasinghe Y; Tan J; Gertig DM; Pitts M; Garland SM
BMC Cancer; 2013 Jun; 13():296. PubMed ID: 23777549
[TBL] [Abstract][Full Text] [Related]
34. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
[TBL] [Abstract][Full Text] [Related]
35. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
Falcaro M; Soldan K; Ndlela B; Sasieni P
BMJ; 2024 May; 385():e077341. PubMed ID: 38749552
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of HPV vaccination against high grade cervical lesions in Japan.
Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
Vaccine; 2018 Dec; 36(52):7913-7915. PubMed ID: 29778520
[TBL] [Abstract][Full Text] [Related]
37. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
Garland SM; Paavonen J; Jaisamrarn U; Naud P; Salmerón J; Chow SN; Apter D; Castellsagué X; Teixeira JC; Skinner SR; Hedrick J; Limson G; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Del Rosario-Raymundo MR; Catteau G; Descamps D; Struyf F; Lehtinen M; Dubin G;
Int J Cancer; 2016 Dec; 139(12):2812-2826. PubMed ID: 27541373
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
[TBL] [Abstract][Full Text] [Related]
39. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
[TBL] [Abstract][Full Text] [Related]
40. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
